cov khoom siv

Palmitoylethanolamide (PEA) hmoov (544-31-0)

Palmitoylethanolamide (PEA) hmoov yog ib qho kev tsis txaus ua cov fatty acids amide. Nws yog cov pob txha ua kom tsis muaj zog ntawm cov cannabinoid 1 (CB1) thiab cannabinoid 2 (CB2) receptors. Palmitoylethanolamide ua los ntawm kev khi rau qhov tsis paub tseeb cannabinoid receptor uas zoo ib yam li CB2, muaj cov khoom pov thawj kev tiv thaiv, tiv thaiv tsis tau, neuroprotective, thiab anticonvulsant cov khoom hauv vivo. Tsim cov kev tiv thaiv zoo los tiv thaiv kev tiv thaiv los ntawm kev ua kom PPARα, ua raws li kev xaiv agonist rau GPR55 receptors (EC50 = 4, 19 800 thiab> 30 000 nM ntawm GPR55, CB2 thiab CB1 receptors feem).

Chaw Tsim Tshuaj: Batch Production
pob: 1KG / hnab, 25KG / nruas
Wisepowder muaj peev xwm tsim tau thiab muab khoom ntau. Txhua qhov kev tsim khoom raws li cGMP thiab kev tswj hwm nruj, tag nrho cov ntaub ntawv xeem thiab cov qauv muaj.

Palmitoylethanolamide (PEA) hmoov hmoov yeeb yaj kiab

 

Palmitoylethanolamide (PEA) hmoov (544-31-0) Cov Ntaub Ntawv Qhia Txog

lub npe Palmitoylethanolamide (PEA) hmoov
CAS 544-31-0
purity roj solubility , dej solubility, hmoov zoo, hmoov dav dav
Tshuaj lub npe Palmitoylethanolamide

N- (2-Hydroxyethyl) hexadecanamide

Synonyms Palmidrol; Impulsin; 544-31-0; N-palmitoylethanolamine; Palmitinsaeure-beta-hydroxyethylamid; (Hydroxyethyl) palmitamide; 2- (Palmitoylamino) ethanol; 2-Palmitamidoethanol; AM 3112; Loramine P 256; Mackpeart DR 14V; N- (2-Hydroxyethyl) palmitamide; N-Hexadecanoylethanolamine; NSC 23320; Palmitic Acid Monoethanolamide; Palmitic Monoethanolamide
molecular Formula C18H37NO2
molecular Nyhav 299.49
Melting Point 97-98 ° C
InChI Qhov Tseem Ceeb HXYVTAGFYLMHSO-UHFFFAOYSA-N
daim ntawv Crystalline khoom
tsos Dawb rau Off-White hmoov
Ib Sim Neej 0.292 Hnub (12-teev hnub; 1.5E6 OH / cm3)
solubility Soluble hauv DMSO (20 mM), ethanol (25 mM), chloroform, THF (ntawm 30 ° C), thiab DMF (~ 10 mg / ml).
cia mob Khaws rau hauv qhov chaw txias thiab qhuav, cia kom deb ntawm cov hnub ncaj qha
Daim ntawv thov Palmitoylethanolamide yog qhov kev tso tawm kom zoo CB2 cannabinoid receptor agonist thiab xaiv GPR55 agonist
Kuaj Cov Ntaub Ntawv Qhov

 

Palmitoylethanolamide (covPEA) hmoov (544-31-0) hmoov General Piav Qhia

Palmitoylethanolamide hmoov yog ib qho kab mob tsis txaus (cannabinoid) uas pom muaj hauv hlwb, daim siab, thiab lwm cov nqaij mos. Nws yog lub cev tsis muaj zog ntawm cov cannabinoid 1 (CB1) thiab cannabinoid 2 (CB2) receptors, nws tau pom tias ua rau kev tiv thaiv rog fatty acid amide hydrolase (FAAH) ((IC50 = 5.1 μM). Modulates mast cell activation. -nociceptive, tiv thaiv kom tsis txhob mob, tiv thaiv kom txhob mob plab thiab tiv thaiv kab mob tsis haum. Nws yog los ntawm kev ua si N-(ntev-saw-acyl) ethanolamine, ib qho tshuaj endocannabinoid thiab N-(saturated fatty acyl) ethanolamine. kev ua los ntawm kev khi rau ib tus neeg tsis paub txog tus kab mob cannabinoid uas zoo ib yam li CB2 Nws kuj tseem ua txoj haujlwm xaiv ntawm GPR55 receptor

Palmitoylethanolamide hmoov, (tseem hu ua palmitoylethanolamine lossis N-2 hydroxyethyl palmitamide), yog ib qho tseem ceeb tshaj plaws ntawm kev ua kom tsis txhob mob thiab tshuaj tiv thaiv kab mob thiab tau pom tias muaj txiaj ntsig rau ob leeg mob thiab mob mus ntev. nws yog qhov kev xaiv zoo tshaj plaws rau cov pa tshuaj uas yuav ua rau muaj kev mob tshwm sim.

Palmitoylethanolamide hmoov tau siv ntau xyoo nyob rau Netherlands thiab Europe, tab sis txij li xyoo 1990 cov paj laum hauv Teb Chaws Asmeskas tau nce. Nws tau muab cais ua "khoom noj rau lub hom phiaj kho mob" hauv Tebchaws Europe thiab ntxiv rau kev noj zaub mov hauv Asmeskas

 

Palmitoylethanolamide (PEA) hmoov Keeb Kwm

Palmitoylethanolamide (PEA) hmoov, lub ntuj tsim los ntawm ethanolamine thiab palmitic acid, yog ib qhov lipid endogenous uas hloov kho qhov mob thiab mob. Kev txaus siab rau cov khoom tiv thaiv kev tiv thaiv ntawm palmitoylethanolamide hmoov tau sau thawj zaug thaum xyoo 1950 los ntawm Coburn li al. (1954) uas pom tau hais tias pub mis rau npua noj muaj qe ntau cov qe qe tiv thaiv lawv los ntawm kev tsis haum tshuaj. Cov kev tshawb fawb tom qab cais thiab purified palmitoylethanolamide hmoov los ntawm cov nkaub qe thiab txheeb xyuas cov khoom sau ua tsiaj hauv tsiaj. Kev tshawb nrhiav kev txaus siab hauv NAE's tau rov qab nyob rau xyoo 1990 tom qab kev tshawb pom ntawm lwm qhov endogenous NAE, AEA, nrog cov khoom zoo sib xws rau cov nquag ua haujlwm ntawm cannabis. Cloning ntawm cannabinoid receptors (xaiv CBi thiab CB2) thiab lub cim ntawm xaiv CB receptor ligands muab cov cuab yeej txuas ntxiv los ua kom nrawm tshawb nrhiav. Txij thaum ntawd los lub cev tseem ceeb ntawm cov pov thawj sib sau los ntawm cov tsiaj thiab tib neeg cov kev tshawb fawb tau pom tias palmitoylethanolamide hmoov muaj cov khoom siv los tiv thaiv thiab ua kom mob siab thaum muab los ntawm cov kev sib txawv ntawm cov thawj coj.

 

Palmitoylethanolamide (PEA) Mechanism Ntawm Kev Ua

Palmitoylethanolamide hmoov ua kom lub zog txhawb nqa, hlawv roj, thiab tiv thaiv kev mob PPAR alpha. Los ntawm kev ua kom cov protein tseem ceeb no, Palmitoylethanolamide hmoov nres cov haujlwm ntawm cov noob caj noob ces thiab tsim ntau yam tshuaj lom.

Palmitoylethanolamide hmoov txo cov kev ua haujlwm ntawm bliss gene FAAH uas zom cov cannabinoid anandamide ntuj. Qhov no nce qib ntawm kev siab tus anandamide hauv koj lub cev, pab rau kev tawm tsam kom tsis txhob mob thiab nce ntxiv. Nws kuj tseem tuaj yeem qhib cov cannabinoid receptors (CB2 thiab CB1).

Palmitoylethanolamide hmoov muaj cov palmitic acid nyob hauv nws cov qauv. Qhov chaw pib rau kev ua Palmitoylethanolamide hmoov hauv lub cev yog qhov tseeb tias cov roj ntsha muaj roj ntau.

Txawm li cas los xij, tsuas yog nce koj kev nqus ntawm palmitic acid los yog lwm yam kev noj haus hauv lub cev yuav tsis cuam tshuam rau Palmitoylethanolamide hmoov ntau lawm hauv lub cev. Qhov no yog vim tias koj lub cev yuav siv Palmitoylethanolamide hmoov tsuas yog thaum nws xav tau los ua kev them nyiaj rau mob lossis mob, thiab nws cov qib yuav tseem txawv txhua hnub. Txoj hauv kev zoo tshaj plaws kom tau txais cov txiaj ntsig ntawm Palmitoylethanolamide hmoov yog cov qauv tshuaj ntxiv, lossis lwm txoj Palmitoylethanolamide hmoov-nplua nuj zaub mov.

 

Daim Ntawv Thov Palmitoylethanolamide (PEA)

Palmitoylethanolamide (PEA) hmoov yog ib qho kev ua rau fatty acid amide endogenous fatty acids, uas yog ib qho piv txwv ntawm endocannabinoid anandamide (AEA), uas yog zwm rau tsev neeg ntawm N-acylethanolamines (NAE). NAE raug tso tawm los ntawm cov hlwb hauv teb rau qhov tsis muaj zog. Raws li txhua tus NAEs, kuj yog Palmitoylethanolamide (PEA) Hmoov muaj cov nyhuv hauv zos, thiab nws cov ntaub so ntswg theem tau zoo tswj los ntawm kev sib npaug ntawm kev tsim khoom thiab kev ua tsis zoo. Ob qho kev tso dej nruab nrab, qhia nyob rau hauv cov roj hlwb, tau koom nrog lipid amide degradation: fatty-acid amide hydrolase (FAAH) thiab N-acylethanolamine hydrolyzing acid amidase (NAAA). Palmitoylethanolamide (PEA) Hmoov tau pom tias yuav khi rau cov kab mob hauv lub cell-nucleus (lub zog txais tshuaj) thiab tawm ntau ntau ntawm kev ua haujlwm lom neeg ntsig txog kev mob ntev thiab mob o.

 

Palmitoylethanolamide (PEA) Kev tshawb fawb ntau ntxiv

Palmitoylethanolamide (PEA) Hmoov yog lub ntuj tsim los ntawm lub cev thiab pom hauv cov zaub mov ntau yam. Nws tsis yog opioid. Nws tsis muaj yees. Kev tshawb fawb ua ntej qhia tias Palmitoylethanolamide (PEA) Hmoov tsis tsim cov tshuaj kam rau tshuaj lossis maj mam poob cov hauj lwm ntev mus raws li tshwm sim nrog opioids. Nws tau pom tias muaj kev nyab xeeb rau cov neeg mob uas tsis muaj kev qhia txog kev mob tshwm sim loj heev thiab nws raug txiav txim tias tsis muaj tshuaj lom neeg mob los yog mob ntev ntev. Nws tsis cuam tshuam nrog lwm cov kev kho mob tsis yog nws cuam tshuam nrog kev sib cuam tshuam yeeb tshuaj-tshuaj. Tsis muaj kev paub txog contraindications rau Palmitoylethanolamide (PEA) Hmoov, thiab cov neeg mob uas txo qis raum thiab nplooj siab ua haujlwm tuaj yeem kho nrog Palmitoylethanolamide (PEA) Hmoov, vim nws cov metabolism hauv zos thiab cellular thiab ywj siab ntawm lub raum thiab nplooj siab ua haujlwm. Raws li nrog ntau cov tshuaj, kev nyab xeeb nrog kev siv sijhawm ntev dua 60 hnub tseem tsis tau kawm zoo txawm tias cov ntawv qhia tau sau tseg hauv cov ntawv ntawm kev siv lub sij hawm ntev uas tsis muaj teeb meem tshwm sim.

 

Palmitoylethanolamide (PEA) Kev siv

  • [1] Cruccu G, Di Stefano G, Marchettini P, Truini A.CNS Neurol Tsis Siv Tshuaj Phiaj. 2019 Jul 3. doi: 10.2174 / 1871527318666190703110036. PMID: 31269891
  • [2] Noli C, Della Valle MF, Miolo A, Medori C, Schievano C; Skinalia Soj Ntsuam Kev Tshawb Nrhiav Pawg.Vet Dermatol. 2019 Jun 24. doi: 10.1111 / vde.12764. PMID: 31237065
  • [3] Contarini G, Franceschini D, Facci L, Barbierato M, Giusti P, Zusso MJ Neuroinflammation. 2019 Jun 20; 16 (1): 126. doi: 10.1186 / s12974-019-1514-4. PMID: 31221190
  • [4] Boccella S, Marabese I, Iannotta M, Belardo C, Neugebauer V, Mazzitelli M, Pieretti G, Maione S, Palazzo E. Int J Mol Sci. 2019 Lub Plaub Hlis 9; 20 (7). pii: E1757. doi: 10.3390 / ijms20071757. PMID: 30970677
  • Palmitoylethanolamide (PEA) Puas Muaj Kev Pabcuam Rog Poob?

 

Cov Lus Trending